Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Societe Des Produits Nestle S.a.

Universite Claude Bernard – Lyon1

Poxel

Ens-ecole Normale Superieure De Lyon

Edelris

Amaury Patin

Patrice Andre

Daniel Cravo

Heiko Oertling

Didier Roche

Sophie Hallakou-Bozec

Marine Gilardone

Pauline Radreau

Laurent Meijer

Frederic Destaillats

Carine Blanchard

Vincent Lotteau

Philip Cohen

Claire Boutry

Peter Gregory Goekjian

Francesca Giuffrida

Joris Michaud

Jerome Feige

Sophie Hallakou-bozec

Philippe Olivier Belmont

Elizabeth Forbes-blom

Pascal Stuelsatz

Johann Bosson

Tristan Bourdeau

Sophie Nutten

Ralf Heine

A compound having the formula (1), (2), (3), or (4), or combinations thereof, for use to maintain or increase muscle function and/or mass in a subject, and/or prevent or reduce muscle wasting in a subject, wherein R, R, R, R, Rand Rare independently, a long chain fatty acid having between 16 and 20 carbons.

Dietary butyrate

The present invention concerns a highly selective process for the preparation of an ingredient comprising 1,3-Olein-2-palmitin (OPO), a triglyceride present in human breast milk. The present invention also relates to 1,3-Olein-2-palmitin (OPO) ingredient obtainable by the process.

Synthesis of 1,3-olein-2-palmitin (OPO)

The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.

Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection

Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection

The invention relates to kinase inhibitors of the formula (I) in which &#x2014;Rto R&#x2550;H; ether or polyether, amino; NO; NH-carbamate; NH&#x2014;CO&#x2014;R, with R such as defined above; Nand derivatives thereof of the 1,2,3-triazole type; &#x2014;R=&#x2014;OH; halogen; &#x2014;OR with R such as defined above; OH-carbamate; OH-carbonate; NH, NH-carbamate; NH&#x2014;CO&#x2014;R, with R such as defined above; Nand derivatives thereof of the 1,2,3-triazole type; N(R,R); &#x2014;R'&#x2550;H or a C1-C12 alkyl, &#x2014;R&#x2550;H; R; (R or R&#x2032;)&#x2014;Si, with R such as defined above; optionally substituted aryl, heteroaryl; halogen (iodine); alkynyl; &#x2014;Rand R&#x2550;H, C-Calkyl; &#x2014;Rand R&#x2550;H, R (or R&#x2032;) such as defined above. These compounds can be used as kinase inhibitors in particular for treating cancer.

Tetrahydrocyclopenta[c]acridine derivatives as kinase inhibitors and biological

Growing community of inventors

Lausanne, Switzerland

Amaury Patin